fashion -WSS

fashion

author：leisure time 2025-09-30 13:44:33 - browse：49824

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Gene editing the human germline: What are the risks?

leisure time

WSS

UnitedHealth increases loan offers after Change Healthcare outage

Wellcome Trust names Røttingen as its new CEO

Intermittent fasting comes with a heart risk? Not so fast

Future doctors should be trained to promote social change

Eight reasons why you should get an updated Covid vaccine

Nick Jonas talks about managing diabetes along with his career

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

The high cost of giving birth even with insurance

How doctors and nurses shape Google's AI

After affirmative action ruling, medical educators look to 'holistic review'

Asbestos, a deadly carcinogen, banned by EPA

In age of alternative facts, a scholarly course on calling out crap

UnitedHealth increases loan offers after Change Healthcare outage

Trump demands the U.S. pay no more for drugs than other countries … again

How should state employee insurance handle Wegovy?

After affirmative action ruling, medical educators look to 'holistic review'

Asbestos, a deadly carcinogen, banned by EPA

hotspot

Life sciences deals on track to hit lowest point since 2017

U.K. researchers warn about biases in medical devices, algorithms

Physicians and social media: If you see something, say something?

Creating egg and sperm cells from stem cells raises ethical issues

Leading voice in opioid treatment defends methadone clinic system

Bernie Sanders bashes nonprofit hospitals over their tax breaks

hotspot

leisure time

knowledge

focus